TAGRISSO® (osimertinib): LAURA Patient Support Program
Dear Healthcare provider,
This letter is to inform you that as of July 23, 2025, the AstraZeneca Oncology Patient Support Program (PSP) for TAGRISSO® is expanding the PSP to include TAGRISSO for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy. For this indication, TAGRISSO has been issued market authorization with conditions.
- A validated test is required to identify EGFR mutation-positive status prior to treatment.
- Marketing authorization with conditions was based on the primary efficacy endpoint of progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in subsequent analyses.
Please note that, at this time, there is no free drug program available for the LAURA indication.
The PSP for TAGRISSO’s LAURA indication offers eligible patients:
- Reimbursement navigation support
- Co-payment towards the cost of the drug (up to 40%), for cash-paying patients and those with private insurance
- Access to educational resources
Patient eligibility criteria:
- Must meet Health Canada approved indication
- Must be a resident of Canada and entitled to Canadian benefits
To enroll a new patient in the PSP, please fax a completed enrolment form to 1-877-280-6221 or email it to the AstraZeneca Oncology Patient Support Program at enrollment@AZoncologypsp.ca.
Should you have any questions about the PSP, please do not hesitate to contact us at 1-877-280-6208 (Monday to Friday, from 8:00 AM – 8:00 PM EST). If you have any questions about TAGRISSO, please contact your local AstraZeneca Canada representative.
Regards,
Your Patient Care Coordinator
AstraZeneca Oncology Patient Support Program